Search research articles
Contact Us
Filters
Showing results (31-40 of 42) with videos related to
Page
of 5
Sort By:
The Oncologist
|
May 26, 2021
Prognostic Factors for Overall Survival in Patients with Hormone Receptor-Positive Advanced Breast Cancer: Analyses From PALOMA-3
Hope S Rugo, Massimo Cristofanilli, Sybille Loibl, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
August 29, 2017
Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy
Kevin L Winthrop, Jeffrey R Curtis, Stephen Lindsey, et al.
Health and Quality of Life Outcomes
|
November 11, 2018
Comparison of patient and physician perspectives in the management of rheumatoid arthritis: results from global physician- and patient-based surveys
Allan Gibofsky, James Galloway, Joern Kekow, et al.
The Oncologist
|
January 24, 2021
Long-Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Updated Analysis with up to 5 Years of Follow-Up
Richard S Finn, Hope S Rugo, Karen A Gelmon, et al.
Clinical Breast Cancer
|
December 15, 2019
Progression-free Survival Outcome Is Independent of Objective Response in Patients With Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer Treated With Palbociclib Plus Letrozole Compared With Letrozole: Analysis From PALOMA-2
Hope S Rugo, Richard S Finn, Karen Gelmon, et al.
Future Oncology (London, England)
|
November 2, 2023
The effects of adding palbociclib to endocrine therapy to treat advanced breast cancer: a plain language summary of a study using the PALOMA-2 and PALOMA-3 trial results
Hope S Rugo, Seock-Ah Im, Anil A Joy, et al.
Breast (Edinburgh, Scotland)
|
December 4, 2022
Effect of palbociclib plus endocrine therapy on time to chemotherapy across subgroups of patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer: Post hoc analyses from PALOMA-2 and PALOMA-3
Hope S Rugo, Seock-Ah Im, Anil A Joy, et al.
Inflammatory Bowel Diseases
|
April 4, 2025
Assessment and Impact of Age on the Safety and Efficacy of Etrasimod in Patients With Ulcerative Colitis: A Post Hoc Analysis of Data From the ELEVATE UC Clinical Program
Gary R Lichtenstein, Jessica R Allegretti, Edward V Loftus, et al.
Breast Cancer Research and Treatment
|
July 20, 2020
Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1, TRIO-18)
Richard S Finn, Katalin Boer, Igor Bondarenko, et al.
The Breast Journal
|
August 27, 2019
Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer
Karen A Gelmon, Massimo Cristofanilli, Hope S Rugo, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 42) with videos related to
Sort By:
Page
of 5
The Oncologist
|
May 26, 2021
Prognostic Factors for Overall Survival in Patients with Hormone Receptor-Positive Advanced Breast Cancer: Analyses From PALOMA-3
Hope S Rugo, Massimo Cristofanilli, Sybille Loibl, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
August 29, 2017
Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy
Kevin L Winthrop, Jeffrey R Curtis, Stephen Lindsey, et al.
Health and Quality of Life Outcomes
|
November 11, 2018
Comparison of patient and physician perspectives in the management of rheumatoid arthritis: results from global physician- and patient-based surveys
Allan Gibofsky, James Galloway, Joern Kekow, et al.
The Oncologist
|
January 24, 2021
Long-Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Updated Analysis with up to 5 Years of Follow-Up
Richard S Finn, Hope S Rugo, Karen A Gelmon, et al.
Clinical Breast Cancer
|
December 15, 2019
Progression-free Survival Outcome Is Independent of Objective Response in Patients With Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer Treated With Palbociclib Plus Letrozole Compared With Letrozole: Analysis From PALOMA-2
Hope S Rugo, Richard S Finn, Karen Gelmon, et al.
Future Oncology (London, England)
|
November 2, 2023
The effects of adding palbociclib to endocrine therapy to treat advanced breast cancer: a plain language summary of a study using the PALOMA-2 and PALOMA-3 trial results
Hope S Rugo, Seock-Ah Im, Anil A Joy, et al.
Breast (Edinburgh, Scotland)
|
December 4, 2022
Effect of palbociclib plus endocrine therapy on time to chemotherapy across subgroups of patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer: Post hoc analyses from PALOMA-2 and PALOMA-3
Hope S Rugo, Seock-Ah Im, Anil A Joy, et al.
Inflammatory Bowel Diseases
|
April 4, 2025
Assessment and Impact of Age on the Safety and Efficacy of Etrasimod in Patients With Ulcerative Colitis: A Post Hoc Analysis of Data From the ELEVATE UC Clinical Program
Gary R Lichtenstein, Jessica R Allegretti, Edward V Loftus, et al.
Breast Cancer Research and Treatment
|
July 20, 2020
Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1, TRIO-18)
Richard S Finn, Katalin Boer, Igor Bondarenko, et al.
The Breast Journal
|
August 27, 2019
Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer
Karen A Gelmon, Massimo Cristofanilli, Hope S Rugo, et al.
Page
of 5